Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Lisa Jeffers, Anna Santarsieri, Wendy Osborne, Florian Chevillon, Agathe Vely, Vandita Bhartia, Graham Collins, Aisling Barrett, Maria Marzolini, Lindsay George, Kaljit Bhuller, Cathy Burton, Sharon-Rose Ogome, Nimish Shah, Sunil Iyengar, Laura McDonald, Vivek Radhakrishnan, Harshani Jayakody, Emily Chernucha, Dominic Culligan, Abhinav Mathur, Pamela McKay, Fatima Jamil, Elizabeth Phillips
Institutions: The Christie NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Newcastle University, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Churchill Hospital, University College London Hospitals NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, University Hospitals of Leicester NHS Trust, St James's University Hospital, Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Royal Marsden NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Nottingham University Hospitals NHS Trust, University of Aberdeen, Beatson West of Scotland Cancer Centre, University of Manchester
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417020139